Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
The Daily Grind: Folgers' Formula for Flavor & Familiarity
Tomorrow’s World Today® Podcast
22 minutes
4 months ago
The Daily Grind: Folgers' Formula for Flavor & Familiarity
What do red shirts, the Gold Rush, and sensory testing have in common? Jim Trout, Vice President, Research & Development–Coffee at The J.M. Smucker Company, connects Folgers’ historic roots to its modern innovation. 🧪📜 Featured on: Tomorrow's World Today - S9E4 – Perfect Pour Learn more about this topic: Modern Coffee Innovations Brewing a Better Tomorrow 5 Quick & Creative Iced Coffee Recipes Collaborate with us! Support the show For more information about the innovations that are sh...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
